

HLA-Diagnostik: Histokompatibilität und Immungenetik im klinischen Kontext

Referenzen

1. <https://www.ebi.ac.uk/ipd/imgt/hla/about/statistics/>
2. <https://hla.alleles.org/>
3. Robinson NMAJ: The HLA/MHC System. In: Histocompatibility and Immunogenetics: A Guide for Practitioners. edn. Edited by Oberle V. Weinheim: Wiley-Vch; 2026: 69–84.
4. <https://www.bundesaerztekammer.de/baek/ueber-uns/richtlinien-leitlinien-empfehlungen-und-stellungnahmen/transplantationsmedizin>
5. <https://www.eurotransplant.org/allocation/eurotransplant-manual>
6. Chapman JR: The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation 2010, 89(6):644–645.
7. Heidt S, Haasnoot GW, van Rood JJ, Witvliet MD, Claas FHJ: Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. Kidney Int 2018, 93(2):491–500.
8. Duquesnoy RJ: HLA epitope based matching for transplantation. Transpl Immunol 2014, 31(1):1–6.
9. Bezstarosti S, Heidt S: The Progress and Challenges of Implementing HLA Molecular Matching in Clinical Practice. Transpl Int 2025, 38:14716.
10. Bhaskaran MC, Heidt S, Muthukumar T: Principles of Virtual Crossmatch Testing for Kidney Transplantation. Kidney Int Rep 2022, 7(6):1179–1188.
11. Liwski RS, Greenshields AL, Conrad DM, Murphey C, Bray RA, Neumann J, Gebel HM: Rapid optimized flow cytometric crossmatch (FCXM) assays: The Halifax and Halifaster protocols. Hum Immunol 2018, 79(1):28–38.
12. Lebendspende Reform <https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/lebendorganspende-reform>
13. Cen M, Wang R, Kong W, Deng H, Lei W, Chen J: ABO-incompatible living kidney transplantation. Clin Transplant 2020, 34(9):e14050.
14. Hart A, Singh D, Brown SJ, Wang JH, Kasiske BL: Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review. Clin Transplant 2021, 35(7):e14320.
15. Naesens M, Roufosse C, Haas M, Lefaucheur C, Mannon RB, Adam BA, Aubert O, Bohmig GA, Callemeyn J, Clahsen-van Groningen M et al: The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant 2024, 24(3):338–349.
16. Oellerich M, Budde K, Osmanodja B, Bornemann-Kolatzki K, Beck J, Schutz E, Walson PD: Donor-derived cell-free DNA as a diagnostic tool in transplantation. Front Genet 2022, 13:1031894.
17. Fleischhauer K, Tran TH, Meisel R, Mytilineos J, Dreger P, Kroger N: Donor Selection for Allogeneic Hematopoietic Cell Transplantation. Dtsch Arztebl Int 2023, 120(15):261–268.

18. Arrieta-Bolanos E, Lima ACM, Andreani M, De Santis D, Malard F, Mayor NP, Mehta RS, Meisel R, Pagliuca S, Petersdorf E et al: HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee. *Bone Marrow Transplant* 2026.
19. Shivarov MIaV: Low/Medium-Resolution HLA Typing. In: *Histocompatibility and Immunogenetics: A Guide for Practitioners*. edn. Edited by Oberle V. Weinheim: Wiley-Vch; 2026: 399–411.
20. Geo JA, Ameen R, Al Shemmari S, Thomas J: Advancements in HLA Typing Techniques and Their Impact on Transplantation Medicine. *Med Princ Pract* 2024, 33(3):215–231.
21. Devriese M, Da Silva S, Le Mene M, Rouquie J, Allain V, Kolesar L, Rigo K, Creary LE, Lauterbach N, Usureau C et al: Two-field resolution on-call HLA typing for deceased donors using nanopore sequencing. *HLA* 2024, 103(3):e15441.
22. Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, Dubois V, Horowitz MM, Madrigal JA, Morishima Y et al: Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. *Lancet Oncol* 2012, 13(4):366–374.
23. Shaffer BC, Gooptu M, DeFor TE, Maier M, Bolanos-Meade J, Abboud R, Briggs AD, Khimani F, Modi D, Newcomb R et al: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. *J Clin Oncol* 2024, 42(28):3277–3286.
24. Heinold A: Chimerism Testing in Stem Cell Transplantation. In: *Histocompatibility and Immunogenetics: A Guide for Practitioners*. edn. Edited by Oberle V. Weinheim: Wiley-Vch; 2026: 263–279.
25. Bundesärztekammer: Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020. In.; 2020.
26. Cohn CS: Platelet transfusion refractoriness: how do I diagnose and manage? *Hematology Am Soc Hematol Educ Program* 2020, 2020(1):527–532.
27. Chen X, Zhao Y, Lv Y, Xie J: Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics. *Platelets* 2024, 35(1):2306983.
28. Reda S, Ruhl H: Diagnosis and Management of Immune Platelet Transfusion Refractoriness. *Hamostaseologie* 2026.
29. Kiefel V: Nachweis thrombozytärer Antikörper – aktueller Stand. *Transfusionsmedizin* 2024(14):95–108.
30. Nguyen XD, Klüter H: The SASPA (Simultaneous Analysis of Specific Platelet Antibodies) Assay: Implementation and Performance in the Routine Laboratory Use. *Transfusion Medicine and Hemotherapy* 2006, 33(3):254–259.
31. Costa TH, Bonet-Bub C, Kutner JM: Platelet antibody detection assays: a single-laboratory comparison of MAIPA, PIFT, and microsphere-based multiplex assays Pak-Lx. *Hematol Transfus Cell Ther* 2024, 46 Suppl 5 (Suppl 5):S97–S102.
32. Kiefel V: Determination of Antibodies and Typing in the HPA. In: *Histocompatibility and Immunogenetics: A Guide for Practitioners*. edn. Edited by Oberle V. Weinheim: Wiley-Vch; 2026: 455–466.
33. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM: High association of an HL-A antigen, W27, with ankylosing spondylitis. *N Engl J Med* 1973, 288(14):704–706.
34. Sollid LM: Coeliac disease: dissecting a complex inflammatory disorder. *Nat Rev Immunol* 2002, 2(9):647–655.
35. *Transfusionsmedizin und Immunhämatologie*, vol. 5: Springer Berlin, Heidelberg; 2026.
36. Palou E: Disease Associations with HLA Alleles. In: *Histocompatibility and Immunogenetics: A Guide for Practitioners*. edn. Edited by Oberle V. Weinheim: Wiley-Vch; 2026: 285–300.
37. Warum ist die HLA-Diagnostik so schlecht im Dating? Weil sie immer erst prüfen muss, ob es wirklich ein Match ist.